File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride

TitleFibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride
Authors
Issue Date2010
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
Journal Of Hepatology, 2010, v. 53 n. 5, p. 934-940 How to Cite?
AbstractBackground & Aims: Fibroblast growth factor 21 (FGF21), a hormone primarily secreted by the liver in response to peroxisome proliferator-activated receptor-α (PPARα) activation, has recently been shown to possess beneficial effects on lipid metabolism and hepatic steatosis in animal models. This study investigated the association of FGF21 with nonalcoholic fatty liver disease (NAFLD) in Chinese patients. Methods: Serum FGF21 levels were determined by enzyme-linked immunosorbent assay (ELISA) in 224 NAFLD and 124 control subjects, and their association with parameters of adiposity, glucose, and lipid profiles and levels of liver injury markers was studied. Besides serum concentrations, the mRNA expression of FGF21 in the liver tissue was also quantified by real-time PCR in 17 subjects with different degrees of steatosis, and was correlated with the levels of intrahepatic lipid. The protein levels of FGF21 were determined by quantitative ELISA. Results: Serum FGF21 levels in patients with NAFLD (402.38 pg/ml [242.03, 618.25]) were significantly higher than those in control subjects (198.62 pg/ml [134.96, 412.62]) (p <0.01). In human liver tissues, FGF21 mRNA expression increased with the degree of steatosis. Both FGF21 mRNA expression and serum FGF21 concentrations were positively correlated with intrahepatic triglyceride (TG) having r = 0.692 and r = 0.662, respectively, at p <0.01. Furthermore, the increased expression of FGF21 was accompanied by elevated protein levels in liver tissues. Conclusions: These results support the role of FGF21 as a key regulator of hepatic lipid metabolism in humans, and suggest that serum FGF21 can be potentially used as a biomarker for NAFLD. © 2010 Published by Elsevier B.V. on behalf of the European Association for the Study of the Liver.
Persistent Identifierhttp://hdl.handle.net/10722/163337
ISSN
2015 Impact Factor: 10.59
2015 SCImago Journal Rankings: 4.570
References

 

DC FieldValueLanguage
dc.contributor.authorLi, Hen_US
dc.contributor.authorFang, Qen_US
dc.contributor.authorGao, Fen_US
dc.contributor.authorFan, Jen_US
dc.contributor.authorZhou, Jen_US
dc.contributor.authorWang, Xen_US
dc.contributor.authorZhang, Hen_US
dc.contributor.authorPan, Xen_US
dc.contributor.authorBao, Yen_US
dc.contributor.authorXiang, Ken_US
dc.contributor.authorXu, Aen_US
dc.contributor.authorJia, Wen_US
dc.date.accessioned2012-09-05T05:30:16Z-
dc.date.available2012-09-05T05:30:16Z-
dc.date.issued2010en_US
dc.identifier.citationJournal Of Hepatology, 2010, v. 53 n. 5, p. 934-940en_US
dc.identifier.issn0168-8278en_US
dc.identifier.urihttp://hdl.handle.net/10722/163337-
dc.description.abstractBackground & Aims: Fibroblast growth factor 21 (FGF21), a hormone primarily secreted by the liver in response to peroxisome proliferator-activated receptor-α (PPARα) activation, has recently been shown to possess beneficial effects on lipid metabolism and hepatic steatosis in animal models. This study investigated the association of FGF21 with nonalcoholic fatty liver disease (NAFLD) in Chinese patients. Methods: Serum FGF21 levels were determined by enzyme-linked immunosorbent assay (ELISA) in 224 NAFLD and 124 control subjects, and their association with parameters of adiposity, glucose, and lipid profiles and levels of liver injury markers was studied. Besides serum concentrations, the mRNA expression of FGF21 in the liver tissue was also quantified by real-time PCR in 17 subjects with different degrees of steatosis, and was correlated with the levels of intrahepatic lipid. The protein levels of FGF21 were determined by quantitative ELISA. Results: Serum FGF21 levels in patients with NAFLD (402.38 pg/ml [242.03, 618.25]) were significantly higher than those in control subjects (198.62 pg/ml [134.96, 412.62]) (p <0.01). In human liver tissues, FGF21 mRNA expression increased with the degree of steatosis. Both FGF21 mRNA expression and serum FGF21 concentrations were positively correlated with intrahepatic triglyceride (TG) having r = 0.692 and r = 0.662, respectively, at p <0.01. Furthermore, the increased expression of FGF21 was accompanied by elevated protein levels in liver tissues. Conclusions: These results support the role of FGF21 as a key regulator of hepatic lipid metabolism in humans, and suggest that serum FGF21 can be potentially used as a biomarker for NAFLD. © 2010 Published by Elsevier B.V. on behalf of the European Association for the Study of the Liver.en_US
dc.languageengen_US
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhepen_US
dc.relation.ispartofJournal of Hepatologyen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshFatty Liver - Blooden_US
dc.subject.meshFemaleen_US
dc.subject.meshFibroblast Growth Factors - Blood - Genetics - Physiologyen_US
dc.subject.meshHumansen_US
dc.subject.meshLiver - Metabolismen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPpar Alpha - Physiologyen_US
dc.subject.meshRna, Messenger - Analysisen_US
dc.subject.meshTriglycerides - Metabolismen_US
dc.subject.meshWaist Circumferenceen_US
dc.subject.meshGamma-Glutamyltransferase - Blooden_US
dc.titleFibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglycerideen_US
dc.typeArticleen_US
dc.identifier.emailXu, A:amxu@hkucc.hku.hken_US
dc.identifier.authorityXu, A=rp00485en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.jhep.2010.05.018en_US
dc.identifier.pmid20675007-
dc.identifier.scopuseid_2-s2.0-77957359658en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77957359658&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume53en_US
dc.identifier.issue5en_US
dc.identifier.spage934en_US
dc.identifier.epage940en_US
dc.publisher.placeNetherlandsen_US
dc.identifier.scopusauthoridLi, H=24066677600en_US
dc.identifier.scopusauthoridFang, Q=8934647200en_US
dc.identifier.scopusauthoridGao, F=54971833900en_US
dc.identifier.scopusauthoridFan, J=7402794379en_US
dc.identifier.scopusauthoridZhou, J=7405551093en_US
dc.identifier.scopusauthoridWang, X=36063233400en_US
dc.identifier.scopusauthoridZhang, H=8403025700en_US
dc.identifier.scopusauthoridPan, X=35176494300en_US
dc.identifier.scopusauthoridBao, Y=36062711100en_US
dc.identifier.scopusauthoridXiang, K=7005183250en_US
dc.identifier.scopusauthoridXu, A=7202655409en_US
dc.identifier.scopusauthoridJia, W=34768292900en_US
dc.identifier.citeulike7590893-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats